Shares of Teva Pharmaceutical (NYSE:TEVA) are down today after it reported earnings for its first quarter of Fiscal Year 2023. Adjusted earnings per share came in at $0.40, which missed analysts’ consensus estimate of $0.56 per share. Sales were flat year-over-year, with revenue hitting $3.7 billion. This was $110 million above expectations.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Looking forward, management now expects revenue and adjusted EPS for Fiscal Year 2023 to be in the ranges of $14.8 billion to $15.4 billion and $2.25 to $2.55, respectively. For reference, analysts were expecting $14.92 billion in revenue and an EPS figure of $2.40.
A look at the past five trading days for TEVA stock highlights the level of impact today’s news had on it. Indeed, shares fell over 7% at the time of writing. As a result, investors are now down 3.66% during this timeframe.